McKesson Corporation (MCK) is a pioneering global healthcare services and IT company. Its main objective is to provide pharmaceuticals, medical supplies, and health information technology services, with a primary dedication to delivering patient care securely and efficiently. Founded in 1833, the company is regarded as one of the oldest continually operating businesses in the United States, with a remarkable imprint on the healthcare sector.
Headquartered in Irving, Texas, McKesson is uniquely positioned at the core of healthcare. It operates as an extensive network serving various entities: manufacturers, providers, pharmacies, governments, and patients. With a standing as one of the biggest pharmaceutical distributors in North America, it delivers one-third of all medications used daily in the region.
Moreover, through services like advanced logistics, payment, and distribution solutions, along with innovative technology, business health, and patient engagement, McKesson efficiently ensures that the right medicines, supplies, and services reach the right people at the right time. It specializes in pharmaceutical distribution, health information technology, care management tools, and medical-surgical supplies.
McKesson is strongly committed to creating a healthier and more sustainable environment. They are known for adopting and promoting eco-friendly solutions, contributing to green initiatives, and maintaining environmental standards throughout their operations. The company also holds a firm belief in corporate social responsibility, with a range of programs and collaborations targeted towards improving community health.
Throughout the years, McKesson has been a source of transformative ideas in healthcare, strongly influenced by the profound industry knowledge of its employees. They play a significant role in areas such as oncology, long-term care, chronic illnesses, and specialty drugs.
For its financials, the corporation is a part of the Fortune 500 companies, known for significant revenues and vast operations. As per Bloomberg data, MCK has a market cap of approximately $31.57 billion, remaining one of the giant pharmaceutical players worldwide.
Moreover, the Company’s performance has been commendable, demonstrating consistent growth. As of fiscal year 2020, the company reported revenues of more than $231 billion.
In conclusion, McKesson Corporation remains an influential company within the healthcare sector. Its long history and established position, as well as its continued focus on delivering health care more efficiently, make it a significant player in the marketplace.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This article compares AbbVie and Pfizer, two pharmaceutical giants, for investors looking at 2026. AbbVie is transitioning its focus to newer immunology drugs, while Pfizer is pursuing aggressive acquisitions in oncology and metabolic assets to counter post-pandemic revenue declines and upcoming patent expirations. While both offer significant dividends, Pfizer appears to be the more undervalued stock based on current valuation metrics, despite AbbVie's promising pipeline.
This article compares AbbVie and Pfizer, two pharmaceutical giants, for investors in 2026, analyzing their financial performance, product pipelines, and risk profiles. While AbbVie is transitioning from its Humira era with new immunology leaders, Pfizer is focusing on oncology and metabolic assets through acquisitions, navigating post-pandemic changes and patent expirations. The author ultimately suggests Pfizer is currently undervalued despite AbbVie's promising pipeline, due to Pfizer's lower valuation metrics and recent growth in its oncology business.
McKesson (MCK) recently raised its full-year adjusted EPS guidance, leading to investor reassessment despite a recent share price dip. While the stock has seen strong long-term gains, short-term momentum has cooled, prompting questions about its current valuation. Analysts, based on a "most followed view," suggest McKesson is still 11% undervalued, with a fair value of $980.73, driven by its focus on oncology and access platforms.
/Henry%20Schein%20Canada%20office%20building%20in%20Vaughan%20By%20JHVEPhoto.jpeg)
Henry Schein, Inc. (HSIC) is outperforming the Dow Jones Industrials Average ($DOWI) year-to-date and over the past 52 weeks, driven by strong internal sales, dental merchandise gains, and strategic acquisitions. The company's Q2 results exceeded Wall Street expectations for both EPS and revenue, contributing to a "Moderate Buy" rating from analysts. HSIC continues to focus on digital transformation and long-term growth through its BOLD+1 plan and investments in technology.
This article compares Cardinal Health (CAH) and McKesson (MCK), two major players in U.S. pharmaceutical distribution. While both are positioned for growth and leverage specialty pharmaceuticals and technology, Cardinal Health shows stronger earnings momentum, better valuation, and a more favorable estimate revision trend. McKesson, despite its scale and specialty services, exhibits less valuation differentiation and a weaker momentum score.
The article compares Cardinal Health (CAH) and McKesson (MCK), two direct competitors in U.S. pharmaceutical distribution, evaluating their recent performance, growth strategies, and valuation. It concludes that while both are strong companies, CAH currently presents a more compelling investment due to its stronger projected EPS growth, favorable valuation, and estimate momentum, despite both holding a Zacks Rank #3 (Hold).
McKesson has confirmed that data theft from its August cyberattack is limited to certain third-party applications serving its Oncology & Multispecialty business, affecting patients at cancer centers and specialty practices. The company will notify affected individuals, but has found no indication that its drug distribution business or CoverMyMeds were impacted. While specific details on the number of affected individuals and practices are still emerging, the company advises caution with unexpected communications and suggests monitoring insurance statements.